newsfilter
← Latest News
GlobeNewswire·

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming